Skip to content
Get BIO’s view on everything from health care to biofuels and the bioeconomy. The below articles include BIO statements, opinion, and calls to action, as well as articles and op-eds written by BIO leadership.
The production of sustainable aviation fuel (SAF) should be encouraged to reduce the high carbon emissions from air travel, writes Biotechnology Innovation Organization (BIO) […]
‘Sustainable air travel is within reach’ – with biotech Read More »
Lifesaving science is under attack from potentially deadly misinformation, says the May 9 episode of the I am BIO Podcast, which features Food and
Misinformation is deadly, FDA Commissioner tells BIO’s podcast Read More »
On April 27, a group of bipartisan U.S. Senators and U.S. Representatives reintroduced the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act. The
PASTEUR Act reintroduced in House, Senate Read More »
The House Financial Services Committee met in a marathon session on April 26, working late into the night to consider a package of 15
These bills could help early-stage innovators access working capital Read More »
If you are a regular reader of Bio.News, you likely know that the past two years have been difficult for the biotech market. Investor
As biotech market seeks rebound, economic and political environments are key Read More »
The pace of biotech investment has slowed recently, harming development at the small, new companies that are driving innovation. “Coming down from the heyday
BIO webinar will advise biotech on weathering the slowing investor market Read More »
After weeks of tension, the Supreme Court decided mifepristone can stay… for now. On the evening of April 21, the Supreme Court ruled the
Supreme Court says mifepristone can stay – for now Read More »
Americans are rightly anxious about the increasing prevalence of serious and deadly infections associated with drug-resistant pathogens – also known as antimicrobial resistance (AMR).
We’re losing the fight against superbugs. The time to act is now. Read More »
On Friday, April 14, the Biotechnology Innovation Organization (BIO) weighed in on initial guidance regarding the Drug Price Negotiation Program (Negotiation Program) under the
BIO submits comments on IRA’s Medicare Drug Price Negotiation Program Read More »
The Inflation Reduction Act was meant to be a step forward in improving the affordability and access to innovative medical treatments, but several provisions
Podcast: The impact of the Inflation Reduction Act and EU pharma package on innovation Read More »
